Guest: Dr. Andrew Blauvelt
Presenter: Neal Howard
Guest Bio: Andy Blauvelt hails from Portland, OR, and is President and Investigator at Oregon Medical Research Center, a small business dedicated to performing high quality clinical studies in dermatology. A native of Michigan, he received his undergraduate degree in Electrical Engineering at Purdue University, his medical degree at Michigan State University, and his MBA from Portland State University/Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami from 1989-1992 and in basic immunology and virology at the National Institutes of Health (NIH) from 1992-1996. He has held senior staff positions at the NIH, as Professor of Dermatology and Microbiology at OHSU, and as Chief of Dermatology at the Portland VA Medical Center. Andy’s clinical and research expertise is in immunology, virology, infectious diseases, psoriasis, atopic dermatitis, and biologic therapies for complex medical dermatology patients, having published over 200 papers and spoken across the world on these topics. Dr. Blauvelt was elected into the American Society for Clinical Investigation in 2004, a leading society for physician-scientists, and is an elected member of the International Psoriasis Council, the premier group of psoriasis experts in the world.
Segment overview: Andrew Blauvelt, MD, MBA, President of the Oregon Medical Research Center, discusses the recently FDA approved medication TREMFYA™ (GUSELKUMAB), the first and only biologic that selectively blocks IL-23, a cytokine that is thought to play a key role in plaque psoriasis, for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Transcript – TBU